Bergen

• Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa … Recruiting
  2024-516030-35-00 5 2025-04-30 Multiple myeloma
• Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE. Recruiting
  2024-513779-42-02 4 2025-03-27 Cancer
• Thrombolysis in Factor Xa-inhibitors Trial (SIFT) Recruiting
  2023-509907-34-01 5 2025-03-10 acute ischemic stroke
• eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity) Recruiting
  2023-506289-29-00 6 2025-02-28 Obesity
• Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated gl … Recruiting
  2023-506998-35-00 5 2025-01-08 Glioblastoma
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting
  2023-509994-22-00 5 2024-11-15 cutaneous malignant melanoma
• MOVE-JIA trial Recruiting
  2024-513017-12-00 6 2024-10-24 Juvenile Idiopathic Arthritis
• NeoLIPA: Neoadjuvant LTX-315 in combination with pembrolizumab in resectable stage III/IV melanoma Recruiting
  2023-508649-42-00 4 2024-10-23 Patients with clinically detectable and resectable stage III-IV melano
• An interventional, multi-center, randomized, double blinded, placebo controlled study to investigate semaglutide add-on treatment for metabo … Recruiting
  2023-506109-20-00 5 2024-10-19 Metabolic control in antipsychotic-using patients
• A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease Recruiting
  2022-503128-29-00 10 2024-10-08 Fabry's disease
• BORTEM 17 Recruiting
  2024-515142-16-00 7 2024-10-03 Grade IV recurrent glioma which includes both glioblastoma, classified
• VEX-AZA: Treating VEXAS Syndrome with Azacitidine. A Single-Arm, Multicenter Phase II Study on the Efficacy and Safety of Azacitidine in Pat … Recruiting
  2024-510715-30-00 4 2024-09-26 VEXAS
• Dextroamphetamine Substitution for Amphetamines Dependence: A Randomized Controlled Trial Recruiting
  2023-508291-11-00 4 2024-09-18 Comorbid dependencies to amphetamines and opioids
• The Effect of Topical Tranexamic Acid on Postoperative Complications in Soft Tissue Plastic Surgery. A Multicenter Randomized Controlled Tri … Recruiting
  2023-510381-28-01 6 2024-09-18 Patients undergoing plastic surgical procedures with wounds that would
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis. Recruiting
  2023-506642-23-01 4 2024-08-28 Active Pulmonary Sarcoidosis
• PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH INTEGRATION OF … Recruiting
  2023-510415-19-00 4 2024-08-28 Acute Myeloid Leukemia
• Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting
  2023-507641-29-00 4 2024-07-15 Locally Advanced or Metastatic Solid Tumors
• Prospective comparison of sirolimus against corticosteroids in treatment of patients with active thyroid eye disease Recruiting
  2023-510166-27-01 5 2024-06-22 Thyroid eye disease
• PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma Recruiting
  2022-501993-21-00 4 2024-06-20 Dedifferentiated Liposarcoma
• A Placebo-Controlled, Randomized Double-Blind Parallel Group 12-Month Trial of Fasudil for the Treatment of Early Alzheimer’s Disease Recruiting
  2023-506514-44-00 4 2024-06-11 Alzheimer's disease
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• A phase 1/2 multicenter open-label study to investigate treatment of hydroxyurea (HU) in combination with valproic acid (VPA) or 6- mercapto … Recruiting
  2022-501992-15-00 9 2024-05-21 Acute Myeloid Leukemia (AML)

Showing 73–96 of 237 trials